Review Examines Whether Alcohol Treatment Drugs Could Help Cannabis Users Too
A review of interactions between cannabinoids and alcohol treatment medications (disulfiram, acamprosate, naltrexone) found these drugs may have effects relevant to cannabis use disorder, but evidence remains limited.
Quick Facts
What This Study Found
Cannabis is frequently used alongside alcohol, and many people who use cannabis also take medications for alcohol use disorder (AUD) or alcohol withdrawal. This review examined the interactions between cannabinoids and three common alcohol treatment medications.
Disulfiram, acamprosate, and naltrexone each interact with the endocannabinoid system in different ways. Some preclinical evidence suggests these medications may have effects relevant to cannabis use as well, either through direct pharmacological interactions or through shared neural pathways.
The review also highlighted the complexity of co-occurring cannabis and alcohol use, where medications intended for one substance may inadvertently affect the other. Understanding these interactions is important for clinicians managing patients with both conditions.
Key Numbers
Three alcohol treatment medications reviewed: disulfiram, acamprosate, naltrexone. Each has distinct interactions with the endocannabinoid system.
How They Did This
Narrative review summarizing preclinical and clinical evidence on interactions between cannabinoids and medications used for alcohol use disorder and alcohol withdrawal syndrome.
Why This Research Matters
With no approved medications for cannabis use disorder, repurposing existing alcohol treatment drugs could provide a shortcut to treatment options. Understanding how these drugs interact with the endocannabinoid system is a necessary first step.
The Bigger Picture
The high rate of co-occurring alcohol and cannabis use means clinicians frequently encounter patients using both substances. Understanding the bidirectional interactions between alcohol treatment medications and cannabinoids is essential for safe and effective treatment.
What This Study Doesn't Tell Us
Limited clinical evidence for cannabinoid-specific effects of alcohol medications. Most evidence is preclinical. The review covers a broad topic area with limited depth in specific interactions.
Questions This Raises
- ?Could disulfiram, acamprosate, or naltrexone be repurposed for cannabis use disorder treatment?
- ?Do these medications affect cannabis use patterns in patients being treated for alcohol problems?
Trust & Context
- Key Stat:
- Three alcohol treatment drugs show potential interactions with the endocannabinoid system
- Evidence Grade:
- Narrative review synthesizing mostly preclinical evidence. No systematic search methodology described.
- Study Age:
- Published in 2016. Research on pharmacotherapies for cannabis use disorder has continued to evolve.
- Original Title:
- Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?
- Published In:
- Neurotoxicity research, 30(4), 698-714 (2016)
- Database ID:
- RTHC-01195
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Could alcohol treatment drugs help with cannabis dependence?
Some preclinical evidence suggests alcohol treatment medications interact with the endocannabinoid system in ways that might be relevant, but clinical evidence specifically for cannabis use disorder is very limited.
Is it safe to use cannabis while taking alcohol treatment medications?
This review highlights that interactions exist between cannabinoids and alcohol medications. Patients using both should discuss this with their healthcare provider.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- anger-irritability-quitting-weed-withdrawal
- appetite-after-quitting-weed
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- caffeine-weed-withdrawal
- cannabinoid-hyperemesis-syndrome
- cannabis-withdrawal-complete-guide
- cannabis-withdrawal-severity-levels-mild-moderate-severe
- cannabis-withdrawal-syndrome
- cannabis-withdrawal-syndrome-dsm-5
- cannabis-withdrawal-syndrome-timeline-day-by-day
- cannabis-withdrawal-vs-alcohol-nicotine-opioid-comparison
- creativity-without-weed-quitting-artist-musician
- emotional-after-quitting-weed-crying
- first-week-quitting-weed
- hobbies-after-quitting-weed
- how-long-does-weed-withdrawal-last
- how-long-to-feel-normal-after-quitting-weed
- identity-after-quitting-weed
- leaving-stoner-culture-identity
- marijuana-withdrawal-symptoms
- money-saved-quitting-weed-calculator
- night-sweats-quitting-weed-withdrawal
- one-year-sober-weed
- paws-cannabis-post-acute-withdrawal
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- weed-cravings
- weed-depersonalization-derealization
- weed-paws-withdrawal
- weed-withdrawal-anger
- weed-withdrawal-brain-fog
- weed-withdrawal-chest-tightness-heart-palpitations
- weed-withdrawal-crying-emotional
- weed-withdrawal-depression
- weed-withdrawal-headaches
- weed-withdrawal-irritability
- weed-withdrawal-men
- weed-withdrawal-mood-swings
- weed-withdrawal-nausea
- weed-withdrawal-night-sweats
- weed-withdrawal-no-appetite
- weed-withdrawal-sweating-detox
- weed-withdrawal-timeline
- weed-withdrawal-vs-alcohol
- weed-withdrawal-women
- what-happens-when-you-stop-smoking-weed
Cite This Study
https://rethinkthc.com/research/RTHC-01195APA
Kleczkowska, Patrycja; Smaga, Irena; Filip, Małgorzata; Bujalska-Zadrozny, Magdalena. (2016). Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?. Neurotoxicity research, 30(4), 698-714.
MLA
Kleczkowska, Patrycja, et al. "Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?." Neurotoxicity research, 2016.
RethinkTHC
RethinkTHC Research Database. "Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Usef..." RTHC-01195. Retrieved from https://rethinkthc.com/research/kleczkowska-2016-are-alcohol-antirelapsing-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.